



Hybrid Nanosystems for Anticancer Therapy

Guest Editor:

Dr. Deblin Jana

School of Engineering, Brown
University, Providence, RI 02912,
USA

Deadline for manuscript
submissions:

20 March 2025

Message from the Guest Editor

Dear Colleagues,

Hybrid nanostructures for cancer therapy are innovative platforms that integrate the advantages of nanomaterials and therapeutic agents to enhance cancer treatment. These nanostructures combine the unique properties of various materials, such as metals, polymers, and biomolecules, to achieve multifunctionality in diagnosis and therapy. On the one hand, hybrid nanostructures can improve the delivery and targeting of anticancer drugs, increasing their efficacy while reducing side effects. On the other hand, they can also facilitate synergistic therapies, such as combining photothermal therapy with chemotherapy, to induce more effective cancer cell destruction. Moreover, the nanostructures' ability to incorporate imaging agents enables simultaneous diagnosis and treatment, known as theranostics.

This Special Issue aims to collect recent research in the design and preparation of hybrid nanostructures and focuses on the use of them in biomedical fields, especially for anti-cancer treatment.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma